Embedded Files
DelveInsight’s 2025 report on the Small Cell Lung Cancer Pipeline offers extensive analysis of over 100 companies and more than 100 drugs in development. It features profiles of pipeline therapies across clinical and non-clinical stages, evaluations by product category, development phase, administration route, and molecular type. The report also covers inactive projects in this therapeutic area.
Access DelveInsight’s detailed Small Cell Lung Cancer Pipeline Report to discover emerging treatments, major companies, and future therapeutic landscapes at Small Cell Lung Cancer Pipeline Outlook Report.
Key Highlights from the Small Cell Lung Cancer Pipeline Report
On October 31, 2025, Merck Sharp & Dohme LLC initiated a study with three parts: Part 1 evaluates safety, tolerability, and effectiveness of gocatamig and I-DXd at doses from study MK-6070-001 (NCT: NCT04471727); Part 2 assesses gocatamig's safety in Japan and China; Part 3 examines gocatamig with durvalumab.
On October 29, 2025, Hoffmann-La Roche announced a study in China comparing tiragolumab plus atezolizumab and carboplatin-etoposide (CE) against placebo plus atezolizumab and CE in untreated extensive-stage small cell lung cancer patients.
On October 27, 2025, Daiichi Sankyo launched a study to determine if I-DXd improves objective response rate (ORR) and overall survival (OS) compared to physician's choice in relapsed SCLC.
On October 23, 2025, Mirati Therapeutics Inc. conducted a Phase 2 study of adagrasib monotherapy, randomizing patients between 600 mg BID without food restrictions and 400 mg BID with food, targeting NSCLC with KRAS G12C mutation after prior platinum and checkpoint inhibitor therapy.
On October 23, 2025, Amgen started a study comparing tarlatamab's efficacy to placebo on progression-free survival (PFS) via blinded independent central review (BICR) per RECIST 1.1 and overall survival (OS).
On October 22, 2025, AstraZeneca announced a Phase I/II study assessing the safety, tolerability, and efficacy of rilvegostomig (AZD2936), an anti-TIGIT/anti-PD-1 bispecific antibody, in advanced or metastatic non-small cell lung cancer.
On October 22, 2025, IDEAYA Biosciences began a Phase 1/2 multicenter study evaluating IDE849's safety, efficacy, pharmacokinetics, and immunogenicity in DLL3-expressing tumors, including SCLC.
DelveInsight’s Small Cell Lung Cancer Pipeline analysis reveals a dynamic field with over 100 active organizations developing more than 100 therapies for Small Cell Lung Cancer management.
Leading companies in Small Cell Lung Cancer include Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, and others.
Promising therapies include Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide, and others.
Dive into DelveInsight’s thorough Pipeline Analysis for insights on innovative advancements at Small Cell Lung Cancer Clinical Trials and Studies.
Understanding Small Cell Lung Cancer
Small cell lung cancer is an aggressive lung cancer originating in lung tissues, characterized by rapid, uncontrolled cell growth. It differs from non-small cell lung cancers (NSCLCs) in its clinical and biological traits. Previously called oat cell carcinoma, SCLC typically starts in peribronchial areas and invades bronchial submucosa.
Profiles of Emerging Small Cell Lung Cancer Drugs
AMG 757: Amgen
AMG 757 is a half-life extended (HLE) bispecific T cell engager (BiTE) targeting delta-like ligand 3 (DLL3) and CD3. It is under Phase I trials for prostate cancer and Small Cell Lung Cancer.APG-1252: Ascentage Pharma
APG-1252 is a potent small-molecule inhibitor of Bcl-2 family proteins, designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by blocking Bcl-2 and Bcl-xL to induce apoptosis. It is in Phase I/II trials for SCLC.
Small Cell Lung Cancer Pipeline Insights
The report delivers detailed profiles of companies developing Small Cell Lung Cancer therapies, including the number of treatments per company.
It categorizes therapeutic candidates into early, mid, and late development stages for Small Cell Lung Cancer care.
Companies focus on targeted drug development, with details on active and inactive (dormant or discontinued) projects.
Drugs in development are analyzed by stage, administration route, target receptor, monotherapy or combination, mechanism of action, and molecular type.
Comprehensive review of partnerships (company-to-company and company-academia), licensing deals, and funding to advance the Small Cell Lung Cancer market.
Obtain a detailed review of recent innovations in the Small Cell Lung Cancer Pipeline. Explore DelveInsight’s expert report today at Small Cell Lung Cancer Unmet Needs.
Small Cell Lung Cancer Companies
Key players include Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, and others.
Small Cell Lung Cancer Therapeutic Assessment by Route of Administration
The report classifies pipeline drugs by delivery methods, such as:
Oral
Parenteral
Intravitreal
Subretinal
Topical
Small Cell Lung Cancer Products by Molecule Type
Products are grouped by molecular categories, including:
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Small Cell Lung Cancer Therapeutic Assessment by Product Type
Monotherapy, Combination Therapy, or Both.
Access DelveInsight’s updated report for strategic insights on future therapies and key developments at Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives.
Scope of the Small Cell Lung Cancer Pipeline Report
Coverage: Worldwide.
Small Cell Lung Cancer Companies: Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, and others.
Small Cell Lung Cancer Therapies: Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide, and others.
Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, or Both.
Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.
Discover in DelveInsight’s specialized Pipeline Report—available now at Small Cell Lung Cancer Emerging Drugs and Major Companies.
Table of Contents
Introduction
Executive Summary
Small Cell Lung Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Small Cell Lung Cancer Collaboration Deals
Late Stage Products (Phase III)
Pembrolizumab: Merck & Co
Mid Stage Products (Phase II)
Dostarlimab: GlaxoSmithKline
Early Stage Products (Phase I)
AMG 757: Amgen
Preclinical/Discovery Stage Products
S 055746: Vernalis
Inactive Products
Small Cell Lung Cancer Key Companies
Small Cell Lung Cancer Key Products
Small Cell Lung Cancer- Unmet Needs
Small Cell Lung Cancer- Market Drivers and Barriers
Small Cell Lung Cancer- Future Perspectives and Conclusion
Small Cell Lung Cancer Analyst Views
Small Cell Lung Cancer Key Companies
Appendix
About DelveInsight
DelveInsight is a premier market research and consulting firm focused on healthcare, providing high-quality intelligence and analysis to guide strategic decisions. Our team of industry experts, with deep expertise in life sciences and healthcare, offers tailored solutions and global insights. Reach out for accurate, timely data to stay competitive.
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Google Sites
Report abuse